<DOC>
	<DOCNO>NCT00847301</DOCNO>
	<brief_summary>An observational cohort study safety efficacy generate additional data benefit/risk profile 150 mg dose Pradaxa patient renal impairment</brief_summary>
	<brief_title>Pradaxa ( Dabigatran Etexilate ) 150 mg/q.d . Patients With Moderate Renal Impairment After Hip Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year age moderate renal impairment ( creatinine clearance 3050 ml/min ) undergo elective total hip replacement surgery consent write participation observational study Exclusion criterion : All patient treat Pradaxa 150 mg accord European Summary Product Characteristics ( SPC ) : severe renal impairment ( creatinine clearance &lt; 30 ml/min ) ; elevate liver enzyme &gt; 2 upper limit normal ( ULN ) ; Hepatic impairment liver disease expect impact survival , anaesthesia postoperative indwell epidural catheter , hypersensitivity dabigatran etexilate excipients , active clinically significant bleeding , organic lesion risk bleeding , spontaneous pharmacological impairment haemostasis , concomitant treatment quinidine , protehetic heart valve require anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>